Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy
Major pathologic response can predict survival of patients with resectable stage IIIA non-small cell lung cancer. For patients potentially not achieving major pathologic response after two cycles of neoadjuvant therapy, extended cycles of feasible neoadjuvant therapy are advisable for survival benefits.
Authors
- Wang Lv
- Ziheng Wu (ORCID: https://orcid.org/0009-0001-0898-8493)
- Pinghui Xia
- Jian Hu (ORCID: https://orcid.org/0000-0002-4499-3345)
- Jinglin Cao (ORCID: https://orcid.org/0009-0004-4703-7246)
- Tianyu He
- Ying Zhang (ORCID: https://orcid.org/0000-0002-8500-2958)
- Shihong Zhou
Institutions
- Tongji University (CN)
- Shanghai Pulmonary Hospital (CN)
- Hangzhou Medical College (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Interdisciplinary CardioVascular and Thoracic Surgery
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1093/icvts/ivae213
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China
- Science and Technology Program of Zhejiang Province